Coenzyme A metabolism in fungi: a new frontier in antifungal therapy
Clinical Microbiology Reviews · 11.06.2026 · 39 (2)
DOI: 10.1128/cmr.00307-25 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Microbiology Reviews, erschienen am 11.06.2026. Verfasst von Jae-Yeon Choi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Coenzyme A, Fungi, Mycoses, Antifungal Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Allergy and Infectious Diseases, NIAID NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Fungal infections are the leading cause of mortality among eukaryotic pathogens. They are responsible for approximately 150 million cases of severe illness and 3.8 million deaths annually. This global health threat is exacerbated by the limited arsenal of clinically approved antifungal drugs, particularly for the treatment of life-threatening invasive infections. The rise of multidrug-resistant fungal strains further underscores the urgent need for new classes of antifungals with novel mechanisms of action. In this context, the fungal coenzyme A (CoA) biosynthesis pathway has emerged as a promising therapeutic target due to its essential role in fungal physiology and key differences from its human counterpart. This review explores the critical role of CoA biosynthesis in fungal metabolism and highlights recent advances in the discovery and characterization of novel compounds targeting this pathway. Some of these emerging candidates act both as standalone inhibitors and as broad-spectrum potentiators of existing antifungals through their ability to enhance strain susceptibility and counteract mechanisms of drug detoxification and multidrug resistance. Collectively, these findings establish CoA metabolism as a compelling target for the next generation of antifungal therapies, offering a multipronged strategy to overcome the limitations of current treatment options and reduce fungal-related mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, USA.
- Curatix LLC, Groton, Connecticut, USA.
- Palos Verdes Peninsula High School, Rolling Hills Estates, California, USA.
- Department of Microbial Pathogenesis, Yale School of Medicine, New Haven, Connecticut, USA.
- Department of Pathology, Yale School of Medicine, New Haven, Connecticut, USA.
ORCID-Profile: Jae-Yeon Choi, Abigail Chiang, Choukri Ben Mamoun
Förderung
- National Institute of Allergy and Infectious Diseases
- NIAID NIH HHS
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Choi, J. Y., Chiang, A., & Ben Mamoun, C. (2026). Coenzyme A metabolism in fungi: a new frontier in antifungal therapy. Clinical Microbiology Reviews, 39(2). https://doi.org/10.1128/cmr.00307-25
Vancouver
Choi JY, Chiang A, Ben Mamoun C. Coenzyme A metabolism in fungi: a new frontier in antifungal therapy. Clinical Microbiology Reviews. 2026;39(2). doi:10.1128/cmr.00307-25
BibTeX
@article{Choi2026,
author = {Choi, Jae-Yeon and Chiang, Abigail and Ben Mamoun, Choukri},
title = {Coenzyme A metabolism in fungi: a new frontier in antifungal therapy},
journal = {Clinical Microbiology Reviews},
year = {2026},
volume = {39},
number = {2},
doi = {10.1128/cmr.00307-25}
}
EUVIMED